KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Debt: 2017-2024

Historic Non-Current Debt for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $32.5 million.

  • Aquestive Therapeutics' Non-Current Debt fell 4.20% to $29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year decrease of 4.20%. This contributed to the annual value of $32.5 million for FY2024, which is 18.15% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Non-Current Debt stood at $32.5 million for FY2024, which was up 18.15% from $27.5 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' Non-Current Debt peaked at $51.6 million during FY2021, and registered a low of $27.5 million during FY2023.
  • In the last 3 years, Aquestive Therapeutics' Non-Current Debt had a median value of $32.5 million in 2024 and averaged $31.2 million.
  • In the last 5 years, Aquestive Therapeutics' Non-Current Debt plummeted by 43.11% in 2020 and then surged by 50.17% in 2021.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Non-Current Debt stood at $34.3 million in 2020, then skyrocketed by 50.17% to $51.6 million in 2021, then plummeted by 35.12% to $33.4 million in 2022, then dropped by 17.76% to $27.5 million in 2023, then grew by 18.15% to $32.5 million in 2024.